Jongun Cho

This inventor holds 9 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Intocell, Inc., Legochem Biosciences, Inc., Y-Biologics Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jongun Cho. Retrieved from https://idiyas.com/inventor/jongun-cho

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 14.6

ph-index = 1

Forward Citations = 15(Granted Patents)

Company Filing History:

Legochem Biosciences, Inc.

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12551570 - Compounds comprising cleavable linker and uses thereof (2026-02-17),

2. 12479927 - Compounds comprising cleavable linker and uses thereof (2025-11-25),

3. 12274898 - Substituted benzodiazepines as antibody-drug conjugates (2025-04-14),

4. 12168060 - Antibody-drug conjugates comprising anti-B7-H3 antibodies (2024-12-17),

5. 11807628 - Benzodiazepine derivatives and uses thereof (2023-11-07),

6. 11753431 - Compounds comprising cleavable linker and uses thereof (2023-09-12),

7. 11084801 - Benzodiazepine derivatives and uses thereof (2021-08-10),

8. 10583197 - Antibody-active agent conjugates and methods of use (2020-03-10),

9. 9669107 - Antibody-active agent conjugates and methods of use (2017-06-06),

Title: Inventor Jongun Cho: Pioneering Advances in Antibody-Drug Conjugates and Benzodiazepine Derivatives

Introduction

Jongun Cho is a prominent inventor based in Daejeon, South Korea, known for his significant contributions to the field of biomedical innovations. With a total of six patents to his name, he has focused on developing advanced therapeutic agents, particularly in cancer treatment and longevity.

Latest Patents

Among his latest innovations is the patent for "Antibody-drug conjugates comprising anti-B7-H3 antibodies." This patent revolves around the development of antibody-drug conjugates (ADCs) that feature one or more active agents linked to an anti-B7-H3 antibody via a specialized linker. The patent emphasizes creating monoclonal antibodies and various forms that selectively bind to B7-H3, with potential applications spanning therapeutic, diagnostic, and prophylactic uses. Additionally, Cho has developed patentable "Benzodiazepine derivatives and uses thereof," which involves compounds and methods that may extend lifespan, showcasing his versatility in novel compound development.

Career Highlights

Jongun Cho has made his mark in the biopharmaceutical community, particularly through his work at renowned companies including Intocell, Inc. and Legochem Biosciences, Inc. His expertise in creating targeted therapeutic approaches has been recognized and applied in innovative treatment solutions, establishing him as a valuable contributor to the sector.

Collaborations

Throughout his career, Jongun Cho has collaborated with esteemed colleagues such as Taekyo Park and Sunyoung Kim. These partnerships underline the collaborative spirit within research institutions, fueling advancements in scientific discoveries and potentially leading to groundbreaking therapeutics.

Conclusion

In summary, Jongun Cho's impressive portfolio of patents and collaborative endeavors in Daejeon has established him as an influential inventor in the biomedical field. His innovative approaches to antibody-drug conjugates and life-extending compounds continue to inspire the next wave of research and development in medicine.

Profile summary based on public USPTO records.